ContraFect Corporation

NASDAQ: CFRXHealthcare / Biotechnology / USA
0.3900+0.0100+2.63%Vol 132 8631Y Perf -79.39%
Aug 21st, 2019 16:00
BID0.3800 ASK0.3900
Open0.3800 Previous Close0.3900
Pre-Market- After-Trading0.38
 - -%  -0.01 -2.56%
Target Price
2.50 
Analyst Rating
Strong Buy 1.00
Potencial %
541.03 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)31 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
1.75 
Earnings Date
8th Aug 2019

Today's Price Range

0.38000.3900

52wk Range

0.35002.63

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-15.22%
3 Months
-11.36%
6 Months
-15.22%
1 Year
-79.39%
3 Years
-82.97%
5 Years
-
10 Years
-

Name / TickerPriceChg.Chg.%
CFRX0.39000.01002.63
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.09-0.090.00
Q01 2019-0.100.15250.00
Q04 2018-0.10-0.0820.00
Q03 2018-0.10-0.100.00
Q02 2018-0.10-0.100.00
Q01 2018-0.09-0.090.00
Q04 2017-0.10-0.12-20.00
Q03 2017-0.110.04136.36
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.09-12.50Negative
12/2019 QR-0.09-12.50Negative
12/2019 FY-0.11-57.14Negative
12/2020 FY-0.39-2.63Negative
Next Report Date-
Estimated EPS Next Report-0.09
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume132 863
Shares Outstanding (in ths.)79 410
Trades Count148
Dollar Volume37 272
Avg. Volume903 718
Avg. Weekly Volume178 826
Avg. Monthly Volume118 557
Avg. Quarterly Volume501 413
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ContraFect Corporation

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

CEO: Roger J. Pomerantz

Teplephone: +1 914 207-2300

Address: 28 Wells Avenue, Yonkers 10701, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

47%53%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

News